Development and evaluation of a framework for incorporating pharmacosurveillance in provincial formulary decision-making

We used semi-structured interviews with plan managers and advisors at the outset (a total of 30 in BC, AB, SK, MB, ON, QC, NS, NL, and YT) and conclusion of the project (2 each in BC and ON) to collect information about their use of evidence and the drugs of greatest concern in terms of efficacy, safety, or cost. [...] Closing interviews in BC and ON included a request for feedback on the usefulness/impact of studies done for the drug plans in the preceding 3 years, including our inter-provincial analyses (a total of 10 in BC and 20 in ON). [...] The mandatory presentation of evidence in a clear and structured format is a well- accepted part of the process for drug licensing, and there are clearly defined research methods for producing the evidence on drug safety and efficacy that are the basis for licensing decisions. [...] The idea of developing a well defined and accepted framework for producing and using evidence has been extended from the licensing of drugs at the national level to the inclusion of drugs on provincial drug benefit formularies. [...] Section 1 confirmed the subject's roles and responsibilities within the Branch during the period of study, and ask him/her to describe the kinds of decisions that typically can be/are informed by pharmacosurveillance research of the type described above.